Medication info

Idalbi Tablet 40 mg (Azilsartan Medoxomil Potassium)

Prescription medicationTabletApproval withdrawn
Ingredient · strength
Potassium Azilsartan Medoxomil›42.68mg / 1 tablet
Manufacturer / importer
Celltrion Pharm, Inc.
Appearance
White or nearly white round tablet
Packaging
PTP packaging: 14 tablets, 28 tablets, 30 tablets, 56 tablets, 90 tablets, 98 tablets per carton
Approval status
Approval withdrawn

MFDS item code 201702622 · Approved 2017.05.26

This product's status changed to Approval withdrawn on 2024.03.21. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of essential hypertension
Who uses it
Adults · Children
Adult dosage
1) Adults The recommended initial dose of this medicine is 40 milligrams once daily, with or without food. If blood pressure is not adequately controlled at this dose, the dose may be increased to a maximum of 80 milligrams daily. The blood pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum effect at about 4 weeks. If blood pressure is not controlled with this medicine alone, additional blood pressure-lowering effects may occur when it is used in combination with other antihypertensive agents [diuretics (e.g., chlorthalidone, hydrochlorothiazide) or calcium channel blockers]. 2) Elderly patients No initial dose adjustment is necessary when administering this medicine to patients aged 65 years and older. For very elderly patients (aged 75 years and older) at risk of hypotension, an initial dose of 20 milligrams may be considered. 3) Patients with renal impairment No dose adjustment is necessary in patients with mild to moderate renal impairment. Use with caution in patients with severe renal impairment or end-stage renal disease (ESRD), as there is no experience with the use of this medicine in these patients. Azilsartan is not removed by hemodialysis. 4) Patients with hepatic impairment This medicine is not recommended in patients with severe hepatic impairment because it has not been studied in these patients. Experience with its use in patients with mild to moderate hepatic impairment is limited; close monitoring is recommended, and an initial dose of 20 milligrams may be considered. 5) Patients with intravascular volume depletion In patients with reduced salt levels or a risk of effective circulating blood volume depletion (e.g., those with vomiting or diarrhea or receiving high doses of diuretics), initiate treatment with this medicine under close medical supervision and consider an initial dose of 20 milligrams.
Children's dosage
The safety and efficacy of this medicine in children and adolescents under 18 years of age have not been established.

Ingredients

Importer
Celltrion Pharm, Inc.

Efficacy & effects

Treatment of essential hypertension

  • Essential hypertension
View approved original text

Essential hypertension is a condition where blood pressure is persistently high. This medication is used to control blood pressure and prevent cardiovascular complications.

Dosage and Administration

Adult dosage

1) Adults The recommended initial dose of this medicine is 40 milligrams once daily, with or without food. If blood pressure is not adequately controlled at this dose, the dose may be increased to a maximum of 80 milligrams daily. The blood pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum effect at about 4 weeks. If blood pressure is not controlled with this medicine alone, additional blood pressure-lowering effects may occur when it is used in combination with other antihypertensive agents [diuretics (e.g., chlorthalidone, hydrochlorothiazide) or calcium channel blockers]. 2) Elderly patients No initial dose adjustment is necessary when administering this medicine to patients aged 65 years and older. For very elderly patients (aged 75 years and older) at risk of hypotension, an initial dose of 20 milligrams may be considered. 3) Patients with renal impairment No dose adjustment is necessary in patients with mild to moderate renal impairment. Use with caution in patients with severe renal impairment or end-stage renal disease (ESRD), as there is no experience with the use of this medicine in these patients. Azilsartan is not removed by hemodialysis. 4) Patients with hepatic impairment This medicine is not recommended in patients with severe hepatic impairment because it has not been studied in these patients. Experience with its use in patients with mild to moderate hepatic impairment is limited; close monitoring is recommended, and an initial dose of 20 milligrams may be considered. 5) Patients with intravascular volume depletion In patients with reduced salt levels or a risk of effective circulating blood volume depletion (e.g., those with vomiting or diarrhea or receiving high doses of diuretics), initiate treatment with this medicine under close medical supervision and consider an initial dose of 20 milligrams.

Children's dosage

The safety and efficacy of this medicine in children and adolescents under 18 years of age have not been established.

Precautions

This medication can cause serious harm to the fetus or newborn if used by women in the second and third trimesters of pregnancy. Therefore, it should be discontinued immediately upon confirmation of pregnancy. It should not be used by individuals allergic to this medication or any of its ingredients, pregnant women, and patients with certain kidney diseases or diabetes. In patients with compromised cardiac function or severe renal impairment, or those with narrowed renal arteries, this medication should be used cautiously, and blood pressure and kidney function should be monitored frequently. Taking this medication with other antihypertensives may increase the risk of side effects such as hypotension, hyperkalemia, and decreased renal function, so co-administration should be avoided. Patients with reduced blood volume or low salt levels may experience hypotension at the outset of treatment, so their status needs to be carefully assessed before administration, and appropriate measures should be taken if necessary. Taking this medication alongside potassium-sparing diuretics or potassium supplements may dangerously elevate serum potassium levels, necessitating periodic monitoring of potassium levels. This medication may cause side effects such as dizziness, hypotension, nausea, rash, and fatigue, particularly in the elderly or patients with impaired renal function, where the likelihood of side effects is increased. Caution is advised when driving or operating machinery, as dizziness or drowsiness may occur. Patients taking lithium or nonsteroidal anti-inflammatory drugs (NSAIDs) should consult their doctor, as side effects or efficacy changes may occur. Pregnant or nursing women are advised to avoid using this medication, especially during breastfeeding, as the drug may be transmitted through breast milk and its safety has not been established. In case of overdose, hypotension and dizziness may occur, and medical attention should be sought immediately for appropriate treatment. This medication should be kept out of reach of children and stored in its original packaging away from light and moisture.

Side effects

  • Dizziness
  • hypotension
  • diarrhea
  • nausea
  • rash
  • pruritus
  • angioedema
  • muscle spasms
  • fatigue
  • peripheral edema
Show 33 more
  • increased serum creatine phosphokinase
  • increased serum creatinine
  • increased serum uric acid
  • headache
  • nasopharyngitis
  • chest discomfort
  • constipation
  • vomiting
  • bad breath
  • asthenia
  • dyspnea
  • dyslipidemia
  • hypercholesterolemia
  • gout
  • hyperkalemia
  • arthralgia
  • myalgia
  • musculoskeletal rigidity
  • increased aspartate aminotransferase
  • urinary tract infection
  • upper respiratory infection
  • acute kidney injury
  • diabetic nephropathy
  • dermatitis
  • urticaria
  • hair loss
  • subdural hemorrhage
  • irregular menstruation
  • worsening hypertension
  • chest pain
  • palpitations
  • syncope
  • total syncope

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a container that protects it from light and air, at a temperature between 1°C and 30°C. It is also important to avoid storing it in humid locations.

Appearance and packaging

Appearance

White or nearly white round tablet

Package unit

PTP packaging: 14 tablets, 28 tablets, 30 tablets, 56 tablets, 90 tablets, 98 tablets per carton

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.